Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
about
Idiotype vaccination for Non-Hodgkin lymphomaIdiotype vaccination for Non-Hodgkin lymphomaEnhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cellsA novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityrEvaluation of current cancer immunotherapy: hemato-oncologyGeneration in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysatePlacebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphomaSurface immunoglobulin on B lymphocytes as a potential target for specific peptide ligands in chronic lymphocytic leukaemia.Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?Molecular analysis of immunoglobulin genes in multiple myeloma.Active idiotypic vaccination versus control immunotherapy for follicular lymphomaDendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma.Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphomaAdoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation.Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in miceTumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regionsImmunotherapy: on the edge between experimental and clinical oncology.Gene therapy: development of immunostimulatory treatments for cancer.In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II studyDendritic cells and immunotherapy for malignant disease.Bone Marrow TransplantationCurrent Clinical Practice: High-Dose Chemotherapy and Stem Cell Transplantation for Non-Hodgkin's Lymphoma: Review of Recent Advances.The biology of human lymphoid malignancies revealed by gene expression profiling.Reflections on the cost consequences of the new gene technology for health policy.Dendritic-cell-based therapeutic cancer vaccinesMultiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders.Vaccine therapy of B cell malignancies: different strategies for a novel approach.Mimotope vaccines: epitope mimics induce anti-cancer antibodiesCurrent therapy and future prospects in lymphoma.Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses.Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plantsAnti-idiotype antibody vaccine therapy for cancer.Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma
P2860
Q24186272-3EF9B590-A253-43B9-B179-0164E36665BEQ24235281-B346E808-BFEF-4CB6-9B1C-81BF60C759C1Q24658494-507A820B-512A-4D1C-839B-02637DD5BFCAQ24681501-B57C18D8-FA49-4507-98E3-7A84B4272443Q26776480-5686ACB3-07D9-46D4-B4D1-A736082C49C5Q27006179-9065DA2C-25F9-43D8-9403-7A6E1A29264DQ28362580-C8998804-0058-4E2E-B91D-D0DDED66512DQ30419228-65260C6F-690E-42A1-BF9D-17F7FB27A1A4Q31038915-FF85C50E-98E3-4608-89AA-16926E92EC41Q33386521-67548873-562E-4E35-89E0-510FBC93F54EQ33536297-9A11363E-56DF-4A2F-8724-1261D9C789D5Q33604355-14AA73D1-6873-4063-9D67-6D0BD646E91DQ33691505-6A099517-B6E9-492D-8F4A-FCFF9982786AQ33762537-6318D0B7-5A9B-4994-B89A-A4DDA7692A1AQ33785039-0CEC4DDD-F285-4B9F-B298-D393DCED86F5Q33814247-46FC7D06-7D25-445A-8138-D7F2AF81A212Q33895386-46DC405D-2CDB-4FFC-AECB-41ECD7E080F1Q33989839-43BFE431-9676-45A8-87D4-6012CF951BADQ34038839-61DC960C-423B-457B-A93D-1D857CB5660DQ34075717-DC65FE3F-1228-4126-ABD8-FAC729F48334Q34097414-2CFBA0CC-81E9-449F-AD5F-5157C4AB8EDEQ34110768-FF4D2213-73AA-4AD5-8253-FE283160858EQ34172095-A8810B03-F2C2-4EDA-848D-44BB33576492Q34187915-C1EEF5C5-FAF2-41F2-B34D-8E9251662AD1Q34194680-66E97C74-3ADE-4476-A267-6F99A305AB51Q34216506-45242AD9-8EF2-42E3-801C-61578DE9A64AQ34278284-82469328-F4C4-439A-AF71-F835574634A6Q34313320-3E509397-E303-48AC-BA02-AB9EF400D794Q34317706-6DE1FE99-A41C-4442-9C08-066BBA73FC79Q34360094-7A50E5EF-FD11-4A1B-9CE1-3AB7A034A3DBQ34427560-74C4A030-8BE1-42D9-80EB-085D8C322063Q34430359-028547F1-E84F-4227-AB39-BF8BF275327BQ34655015-D03D5692-CD9E-437E-8D46-C12401206E91Q34734296-CED63315-7D81-4CAD-BDE1-276048F8C1B2Q34734310-DE2C95B3-2274-4ECB-A4CF-5C4ECB121641Q34791108-4744CB46-B40B-40BD-9FE9-E189E26C67D0Q34849268-E3F5FF3E-A8A1-4B4E-8026-23B5B515D225Q35040841-17128030-B2B3-4D21-87ED-D173EAC34272Q35113388-48A73406-BD63-4F33-A76C-CCDF4CB63E8EQ35114545-2994B59B-4531-4435-9BC5-A0BEF079ED39
P2860
Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Induction of immune responses ...... ype expressed by their tumors.
@en
Induction of immune responses ...... ype expressed by their tumors.
@nl
type
label
Induction of immune responses ...... ype expressed by their tumors.
@en
Induction of immune responses ...... ype expressed by their tumors.
@nl
prefLabel
Induction of immune responses ...... ype expressed by their tumors.
@en
Induction of immune responses ...... ype expressed by their tumors.
@nl
P2093
P1476
Induction of immune responses ...... ype expressed by their tumors.
@en
P2093
P304
P356
10.1056/NEJM199210223271705
P407
P577
1992-10-01T00:00:00Z